Elute, Inc

Executive Summary

Elute, Inc. is a clinical-stage biotechnology company developing patented drug-eluting devices for controlled and sustained therapeutic release, with an initial focus on orthopedic infections. Its lead product, BonVie+™, is a resorbable bone graft substitute designed to restore bone loss and deliver local antibiotics to prevent recurrent infections. The company addresses a significant unmet clinical need in orthopedics, where current treatments for bone infections (osteomyelitis) often involve multiple surgeries and systemic antibiotics. Elute's technology aims to provide a one-step solution that promotes bone healing while reducing infection recurrence. As a private company founded in 2018 and currently in Phase 1, Elute has limited public financial data but operates in a large market with strong demand for improved infection control in orthopedic surgery.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 Clinical Trial Results for BonVie+60% success
• Q2 2026FDA Meeting or IND Update70% success
• TBDStrategic Partnership or Licensing Deal40% success